Latest Issue
Latest Issue
Leah SherwoodMeeting News | February 8, 2024
The meeting had more than 2,500 registrants attending in person or online.
Read More
Cecilia BrownAcute Lymphoblastic Leukemia | October 11, 2023
JZP458, which is approved in the United States and Canada, is a new Erwinia-derived asparaginase.
Cecilia BrownAcute Myeloid Leukemia | February 8, 2024
The retrospective, observational study included adults who received their first allogeneic HSCT during their first remission.
Cecilia BrownChronic Lymphocytic Leukemia | February 8, 2024
Dr. Coombs discusses her journey into oncology, what it’s like to broach the lymphoid and myeloid worlds, and a unique ...
Leah LawrenceMyeloma | February 8, 2024
Researchers and clinicians are attempting to make clinical trials better reflect the population of patients with MM.
Othman Al-Sawaf, MDChronic Lymphocytic Leukemia | September 24, 2023
Othman Al-Sawaf, MD, and Nicole Lamanna, MD, debate approaches in this Point | Counterpoint.
Cecilia BrownMantle Cell Lymphoma | September 19, 2023
Researchers conducted the study because patients with TP53-mutated disease “have poor outcomes with standard approaches."
Cecilia BrownMyelofibrosis | October 11, 2023
Researchers conducted an indirect comparison analysis of multiple clinical trials to address the question.
Cecilia BrownMyeloma | September 19, 2023
It is approved as a weekly or biweekly subcutaneous injection after an initial step-up phase.
Cecilia BrownAggressive B-Cell Lymphoma | September 19, 2023
The application for the approval of epcoritamab is based on results from the phase I/II EPCORE NHL-1 trial.
Cecilia BrownMyeloma | July 27, 2023
The supplemental BLA submission is supported by data from the CARTITUDE-4 study.
Leah SherwoodMyeloma | August 14, 2023
The FDA has put a clinical hold on the investigational new drug CART-ddBCMA.
Cecilia BrownMeeting News | September 20, 2023
Dr. Mascarenhas and colleagues identified 11,371 patients with myelofibrosis, finding that 76.8% had concurrent anemia.
Leah SherwoodChronic Lymphocytic Leukemia | February 8, 2024
Dose reduction may be a strategy to mitigate the risk of cardiac AEs from recurring or worsening in B-cell malignancies.
Cecilia BrownMyelodysplastic Syndromes | February 8, 2024
Luspatercept-aamt demonstrated “favorable outcomes” compared with epoetin alfa across common mutations in MDS.
Cecilia BrownMantle Cell Lymphoma | September 5, 2023
The estimated seven-year EFS rate was 76.7% in patients receiving rituximab maintenance.
Cecilia BrownAcute Myeloid Leukemia | September 20, 2023
Revumenib is a potent, selective oral inhibitor of interaction between menin and KMT2A.
Cecilia BrownMyelodysplastic Syndromes | February 7, 2023
Exposure to thalidomide analogs is associated with TP53 mutations in patients with therapy-related myeloid neoplasms.
Laurie Sehn, MD, MPHAggressive B-Cell Lymphoma | February 7, 2023
Given the multitude of novel therapies recently approved, clinicians must consider how to best sequence the options.
Leah LawrenceAggressive B-Cell Lymphoma | February 7, 2023
CAR-T therapy leads to responses in most patients with aggressive B-cell lymphoma, but durable CRs only occur in a minority.
Editorial Board